January 18, 2013 at 10:19 AM EST
NuPathe I(PATH) soared on FDA approval
Normal 0 false false false MicrosoftInternetExplorer4 Shares of NuPathe Inc. (NASDAQ: PATH) soared 10.5% to $3.67 after the specialty pharmacy company said the previous day that the U.S. Food and Drug Administration has approved its Zecuity drug for the acute treatment of migraines. Share volume was 541,000 an all-day average of 44,000 /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman"; mso-ansi-language:#0400; mso-fareast-language:#0400; mso-bidi-language:#0400;}
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here